In this article, we will list the 5 Best Stem Cell Therapy Stocks to Buy. If you wish to see the methodology behind the article and the extended list, please visit 8 Best Stem Cell Therapy Stocks to Buy.
A scientist in a lab coat looking through a microscope at a petri dish of hematopoietic stem cells.
5. Amgen Inc. (NASDAQ:AMGN)
Amgen Inc. (NASDAQ:AMGN) is one of the best stem cell therapy stocks to buy. Canaccord initiated coverage of Amgen Inc. (NASDAQ:AMGN) with a Hold rating on April 21, setting a price target of $366. The firm told investors in a research note that the company has executed well on its key growth drivers, but this is reflected in the stock’s good performance since last October. It further stated that it believes Amgen Inc.’s (NASDAQ:AMGN) current valuation to be appropriate, adding that meaningful appreciation from here “could be more challenging” because of some loss of exclusivities and pricing pressure across several of its large mature products.
For additional perspective, in its fiscal Q4 and full year 2025 results, Amgen Inc. (NASDAQ:AMGN) reported strong performance in the full year with double-digit growth in revenues and EPS. Total revenues for fiscal Q4 rose 9% to $9.9 billion compared to the prior year period, with product sales growing 7%, driven by 10% volume growth. Total revenues for the full year reached $36.8 billion, up 10% compared to the same quarter last year.
Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.
4. Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best stem cell therapy stocks to buy. Gilead Sciences, Inc. (NASDAQ:GILD) announced on April 17 the attainment of all required regulatory approvals for its previously announced acquisition of Arcellx. The company also stated that it has extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx.
In a separate development, Gilead Sciences, Inc. (NASDAQ:GILD) received a rating update from Truist on April 8, with the firm lifting the price target on the stock to $155 from $152 while reaffirming a Buy rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 earnings in Biotech, with the firm stating that reactivity to regulatory and policy shifts across the sector is continuing to ease.
Truist also noted a recent pickup in deal activity, which it believes holds the potential to build momentum through the remainder of the year into midterms. The firm further told investors in a research note that for Gilead Sciences, Inc. (NASDAQ:GILD), it is looking for its management commentary on Yeztugo launch strategy and payer access dynamics in the U.S./EU markets, along with any anito-cel launch preparation updates ahead of the December 23, 2026, PDUFA.
Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19. Its portfolio of drugs focuses on medical areas with unmet needs, and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others.
3. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best stem cell therapy stocks to buy. TD Cowen lifted the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $960 from $880 on April 23, reaffirming a Buy rating on the shares. The firm updated its model ahead of the fiscal Q1 results, and slightly decreased Eylea and Libtayo estimates and increased Dupi estimate, while bringing the non-GAAP EPS estimate for fiscal Q1 up to $9.30.
The rating update came the same day Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Otarmeni™, which is the first gene therapy and second new molecular entity approved under the FDA Commissioner’s National Priority Voucher program.
Management reported that Otarmeni is an “adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss associated with molecularly confirmed biallelic variants in the OTOF gene, preserved outer hair cell function, and no prior cochlear implant in the same ear”. Formerly known as DB-OTO, Otarmeni is the first and only in vivo gene therapy for OTOF-related hearing loss, and will be made available by Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for free in the United States.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a pharmaceutical company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions.
2. AbbVie Inc. (NYSE:ABBV)
AbbVie Inc. (NYSE:ABBV) is one of the best stem cell therapy stocks to buy. On April 23, Piper Sandler cut the price target on AbbVie Inc. (NYSE:ABBV) to $294 from $299 while reaffirming an Overweight rating on the shares. The rating update came ahead of the quarterly results, with the firm saying that the company has become a bit controversial. Despite that, Piper is making a case for why there is no need for investors to worry, as the primary worry on AbbVie Inc. (NYSE:ABBV), as seen by the firm, is driven in part by the rollout of oral IL-23-directed treatment Icotyde by Johnson & Johnson in the psoriasis setting, along with how it could impact the trajectory of Skyrizi.
The firm would anticipate that Icotyde will likely expand the overall footprint of the IL-23 category, adding that Skyrizi penetration in inflammatory bowel disease is still quite low. It also stated that although the consensus estimates on Skyrizi may have caught up with its growth trajectory, there are other parts of the business where that is not the case.
AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.
1. Thermo Fisher Scientific Inc. (NYSE:TMO)
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best stem cell therapy stocks to buy. On April 23, Thermo Fisher Scientific Inc. (NYSE:TMO) announced financial results for fiscal Q1 2026. Revenue for the quarter rose 6% to $11.01 billion, compared to $10.36 billion in the same quarter last year. Organic revenue underwent a 1% growth. Management further reported that the GAAP diluted EPS in fiscal Q1 2026 was $4.43, reflecting an 11% growth compared to the prior year period. GAAP operating income for the quarter reached $1.86 billion, up 9% versus the year-ago quarter, while GAAP operating margin was 16.9%, compared with 16.6% in fiscal Q1 2025.
Thermo Fisher Scientific Inc. (NYSE:TMO) also stated that it advanced its proven growth strategy, launching a range of high-impact and innovative products during the quarter. This included a Thermo Scientific™ Glacios™ 3 Cryo-TEM, the Thermo Scientific™ TSQ Certis™ triple quadrupole mass spectrometer, the Thermo Scientific™ Niton™ XL5e Handheld XRF Analyzer, and the Gibco™ CTS™ Compleo™ Fill and Finish System.
Thermo Fisher Scientific Inc. (NYSE:TMO) provides analytical instruments, reagents, equipment, software, and other services for analysis, research, diagnostics, and discovery. It operates through the Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Diagnostics segments.
While we acknowledge the potential of TMO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TMO and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
